Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare today announced that Bayer's Japanese subsidiary, Bayer Yakuhin, Ltd. ("Bayer Yakuhin"), and Santen Pharmaceutical Co., Ltd.("Santen")entered into a co-promotion agreement for EYLEA® (aflibercept) Injection in Japan.  As previously announced, Bayer Yakuhin has submitted an application for marketing authorization to the Ministry of Health, Labor and Welfare (MHLW) for EYLEA for the treatment of neovascular age-related macular degeneration (wet AMD).

"With this agreement and upon marketing authorization, a newly formed Bayer Yakuhin ophthalmology field force and Santen, the leading ophthalmology company in Japan, will promote EYLEA," said Sebastian Guth, President & CEO of Bayer Yakuhin, Ltd.  "We expect that the combined resources of the two companies will allow EYLEA to achieve a broader and faster reach into the Japanese ophthalmology community and potentially benefit a greater number of patients."

Bayer and Regeneron have also amended their existing global license and collaboration agreement for EYLEA to convert the 50/50 profit share for Japan into a royalty arrangement that approximates the economics of the profit split.  In certain specified circumstances, the royalty may revert to a profit share arrangement.

EYLEA is approved for sale in the United States for the treatment of wet AMD and marketing approval has also been granted in Australia.  Bayer HealthCare has submitted applications in Europe and other countries and has initiated a Phase 3 clinical study for wet AMD in China. Beyond the wet AMD indication, EYLEA is in Phase 3 clinical studies for the treatment of diabetic macular edema (DME), myopic choroidal neovascularization (mCNV), and branch retinal vein occlusion (BRVO).  Regeneron has filed an sBLA for EYLEA in central retinal vein occlusion (CRVO) in the United States, and has been granted a Prescription Drug User Fee Act (PDUFA) date of September 23, 2012.

Bayer HealthCare and Regeneron Pharmaceuticals, Inc. are collaborating on the global development of EYLEA®.  EYLEA was approved in the United States for the treatment of wet AMD in November 2011.  Regeneron maintains exclusive rights to EYLEA in the United States.  Bayer HealthCare owns the exclusive marketing rights outside the United States, where the companies will share equally the profits from any future sales of EYLEA, except for Japan where Regeneron will receive a royalty on net sales.

SOURCE Regeneron Pharmaceuticals, Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Santen Pharmaceutical Co., Ltd.. (2012, May 08). Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan. News-Medical. Retrieved on August 18, 2019 from https://www.news-medical.net/news/20120508/Bayer-Yakuhin-Santen-enter-co-promotion-agreement-for-EYLEA-Injection-in-Japan.aspx.

  • MLA

    Santen Pharmaceutical Co., Ltd.. "Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan". News-Medical. 18 August 2019. <https://www.news-medical.net/news/20120508/Bayer-Yakuhin-Santen-enter-co-promotion-agreement-for-EYLEA-Injection-in-Japan.aspx>.

  • Chicago

    Santen Pharmaceutical Co., Ltd.. "Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan". News-Medical. https://www.news-medical.net/news/20120508/Bayer-Yakuhin-Santen-enter-co-promotion-agreement-for-EYLEA-Injection-in-Japan.aspx. (accessed August 18, 2019).

  • Harvard

    Santen Pharmaceutical Co., Ltd.. 2012. Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan. News-Medical, viewed 18 August 2019, https://www.news-medical.net/news/20120508/Bayer-Yakuhin-Santen-enter-co-promotion-agreement-for-EYLEA-Injection-in-Japan.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Santen announces Phase III results of sirolimus intravitreal injections in non-infectious posterior segment uveitis patients